[ABSTRACT] Controlled studies concerning pharmacological management of psychotic, treatment-resistant depression are scarce. Subjects as efficacy of new antipsychotics and antidepressants, safety and interactions of combinated new drugs, decision-trees on 2nd and 3rd lines of prescription, optimal dosage, etc. remain unclear. A case of bipolar disorder, rapid cycling, psychotic depression episode is presented, who was treated with venlafaxine 375 mgr/day, carbamazepine 1000 mgr/day and risperido